Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

Leukemia

Volumn 27, Issue 5, 2013, Pages 1028-1036

  Craddock, C ^a,b   Quek, L ^c,d   Goardon, N ^c   Freeman, S ^a,b   Siddique, S ^a,b   Raghavan, M ^a,b   Aztberger, A ^c   Schuh, A ^d   Grimwade, D ^e,f   Ivey, A ^e,f   Virgo, P ^g   Hills, R ^h   McSkeane, T ^a,b   Arrazi, J ^a   Knapper, S ^h   Brookes, C ^b   Davies, B ⁱ   Price, A ⁱ   Wall, K ^j   Griffiths, M ^j   Cavenagh, J ^k   Majeti, R ^l   Weissman, I ^l   Burnett, A ^h   Vyas, P ^c,d   more..

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g NORTH BRISTOL NHS TRUST   (United Kingdom)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j West Midlands Regional Genetics Laboratory   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

acute myeloid leukemia; azacitidine; disease relapse; epigenetic therapies; leukemic stem cell; myelodysplasia

Indexed keywords

AZACITIDINE; RETINOIC ACID; THEOPHYLLINE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SOMNOLENCE; STEM CELL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASTIC STEM CELLS; PROGNOSIS;

EID: 84877589557     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.312     Document Type: Article

References (26)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
2. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271-3279.
3. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 2302-2308.
4. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli G, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
7. Raffoux E, Cras A, Recher C, Boelle PY, de Labarthe A, Turlure P et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1: 34-42.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
9. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Perace DJ, Allen K, Ridler C et al. Anti- CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-575.
10. Taussig DC, Vargaftig J, Mirak-Moud F, Greissinger E, Sharrock K, Luke T et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115: 1976-1984.
11. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384-395.
12. Eppert K, Takenaka K, Lechman ER, Walsron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093.
13. Goardon N, Marchi E, Atzberger A, Quek L, Shuh A, Soneji S et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138-152.
14. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Katamura H, Tanaka S et al. Chemotherapy- resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321.
15. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S et al. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 1700-1707.
16. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, Eckstein V et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009; 37: 1423-1434.
17. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Mosberger L et al. A clinically relevant population of leukemic CD34+CD38- cells in acute myeloid leukemia. Blood 2012; 119: 3571-3577.
18. Cheson BD, Bennet JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649.
19. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
20. Cox DR. Regression models and life tables. J R Stat Soc. Series B (Methodological) 1972; 34: 187-220.
21. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433.
22. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients withmyelodysplastic syndromes. Leukemia 2011; 25: 1153-1158.
23. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
24. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA, Jang HG et al. Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
25. Figueroa ME, Abdel-Waheb O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
26. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, feller N, Moshaver B et al. The novel AML stem cell associated antigen CLL-1 aids in 483 discrimination between normal and leukemic stem cells. Blood 2007; 110: 2659-2666.